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Methods: Twelve patients with cDGS underwent
transplantation with allogeneic cultured thymus.
Objective: We sought to confirm and extend the results
previously obtained in a single center.
Results: Two patients died of pre-existing viral infections
without having thymopoiesis, and 1 late death occurred from
autoimmune thrombocytopenia. One infant had septic shock
shortly after transplantation, resulting in graft loss and the
need for a second transplant. Evidence of thymopoiesis
developed from 5 to 6 months after transplantation in 10
patients. Median circulating naive CD4 counts were 44 3 106/
L (range, 11-440 3 106/L) and 200 3 106/L (range, 5-
310 3 106/L) at 12 and 24 months after transplantation and T-
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age, but patients were able to clear pre-existing infections and
those acquired later. At a median of 49 months (range, 22-
80 months), 8 have ceased prophylactic antimicrobials, and 5
have ceased immunoglobulin replacement. Histologic
confirmation of thymopoiesis was seen in 7 of 11 patients
undergoing biopsy of transplanted tissue, including 5 showing
full maturation through to the terminal stage of Hassall body
formation. Autoimmune regulator expression was also
demonstrated. Autoimmune complications were seen in 7 of 12
patients. In 2 patients early transient autoimmune hemolysis
settled after treatment and did not recur. The other 5
experienced ongoing autoimmune problems, including
thyroiditis (3), hemolysis (1), thrombocytopenia (4), and
neutropenia (1).
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cDGS: Complete DiGeorge syndrome
CHARGE: Coloboma, heart defects, atresia choanae, retardation of




cTEC: Cortical thymic epithelial cell
CTLA4: Cytotoxic T lymphocyte–associated antigen 4
DGS: DiGeorge syndrome
EpCam: Epithelial cell adhesion molecule
FoxP3: Forkhead box P3
HSCT: Hematopoietic stem cell transplantation
LCL: Lymphoblastoid cell line
mTEC: Medullary thymic epithelial cell
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TEC: Thymic epithelial cell
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DiGeorge syndrome (DGS) with athymia, also known as
complete DiGeorge syndrome (cDGS), results in a state of
profound T-cell deficiency. Causal associations have been re-
viewed elsewhere1; DGS can be associatedwith a hemizygousmi-
crodeletion at chromosome 22q.11, CHARGE (Coloboma, heart
defects, atresia choanae, retardation of growth and development,
genital abnormalities, ear abnormalities/deafness) syndrome, mu-
tations inTBX1, deletions at chromosome 10p13-14, or fetal toxin
exposure from glucose, ethanol, or retinoic acid. Around 1.5% of
children with the 22q.11 deletion have the complete form of
DGS,2 whereas the incidence of the problem in relation to other
causes is unknown. The immunologic phenotype is either of a pro-
foundT-cell lymphopenia, or in patientswith atypical cDGS, there
might be oligoclonal expansions of memory phenotype T cells
conferring little or no protective immunity and causing inflamma-
tory disease in the form of rashes, enteropathy, and lymphadenop-
athy.3 cDGS differs from severe combined immunodeficiency
(SCID) in that the underlying defect prevents development of
the thymus, whereas the underlying defect in SCID is a genetic
defect in the hematopoietic lineage. Patients with both cDGS
and SCID have a similar high risk of early death from infection.
Two approaches have been used to correct the immunodefi-
ciency in patients with cDGS. The first is T cell–replete hemato-
poietic stem cell transplantation (HSCT), but because of the
absence of thymus, this approach can only achieve engraftment of
postthymic T cells. Although there are a number of reports of
long-lasting survival in patients treated in this way, particularly
after matched sibling donor transplantation, the quality of the
immune reconstitution achieved is poor.4 Survival after matched
unrelated donor and matched sibling transplantations were re-
ported as being 33% and 60%, respectively.5 The alternative
approach is to use thymus transplantation, which aims for a
more complete reconstitution with the ability to produce naive
T cells that show a broad T-cell receptor (TCR) repertoire. Post-
natal thymic tissue is readily available because it is routinely
removed from infants undergoing open heart surgery through a
median sternotomy. This approach has been used at a single cen-
ter in the United States since the mid-1990s. There might have
been some patient selection bias in the group undergoing thymus
transplantation because patients with severe comorbidities or
serious opportunistic infections were excluded. Nevertheless,
the results compare very favorably with the outcome of HSCT,
with an approximately 75% long-term survival in 60 patients.6
Evidence of thymopoiesis and a diverse repertoire of naive circu-
lating T cells capable of HLA-restricted specific antigen re-
sponses was seen in survivors. Nonsurvival in this cohort was
mostly associated with pretransplantation morbidity, mainly viral
infections, chronic lung disease, or both.7 Autoimmune
hypothyroidism was relatively common at just over 20%, with
an additional number of patients having this problem before
transplantation.6 More serious and potentially life-threatening
autoimmunity, including immune cytopenias and enteropathy,
was also reported, although much less commonly. The reasons
for the occurrence of these complications are ill-understood.8
A center for thymus transplantation was established in London
to provide this treatment for patients in Europe, whichwas done totest whether the technology could be successfully translated from
the single center and make the treatment approach more readily
available in Europe. This report outlines the results of the first 12
patients treated with more than 24 months of follow-up.METHODS
Patients
Patients were recruited between 2009 and 2014. To qualify for the study,
those with typical cDGS had a maximum T-cell count of 503 106/L, no naive
T cells, and an absent proliferative response to PHA. Patients with atypical
cDGS had less than 5% naive CD4 cells (CD45RA1CD271 or
CD45RA1CD62L1). In addition, there had to be at least 1 of the
following features: congenital heart disease, hypoparathyroidism,
hemizygosity for 22q.11 deletion, or CHARGE syndrome. For further
patient details, see the Methods section in this article’s Online Repository at
www.jacionline.org.
Patients with typical cDGS without clonal expansion were not given any
immunosuppression. In those with atypical cDGS, cyclosporine was used
before transplantation to control inflammatory disease, and this was continued
after transplantation. These patients were also treated with 3 doses of 2 mg/kg
body weight rabbit antithymocyte globulin (ATG; Genzyme, Cambridge,
Mass) and 2mg/kgmethylprednisolone administered intravenously for 4 days,
followed by 1 mg/kg oral prednisolone for 5 days.Obtaining, culturing, and transplanting donor
thymuses
For details, including screening of donors and the transplantation
procedure, which has been described previously,9 see the Methods section
in this article’s Online Repository. Separate thymuses were cultured
specifically for analysis to assess cellular composition changes during the
period of culture. For detailed methods, see the Methods section in this
article’s Online Repository.Laboratory analysis
Flow cytometric analysis, mitogen responsiveness, and measurement of
T-cell receptor signal joint excision circle (TREC) levels involved standard
TABLE I. Patients’ characteristics
Patient/sex/age at
transplantation (mo) Diagnosis CD3 (naive) 3 106/L Other problems and infections present at the time of transplantation
1. Female, 14 and 26* CHARGE syndrome (CHD7) Typical
20 (0)
Atrioventricular canal, hypoparathyroidism, recurrent sepsis, nonspecific
enteropathy, previous B-cell lymphoma, HHV6
2. Male, 8 22q.11.2 deletion Typical
30 (0)
Fallot tetralogy, hypoparathyroidism, Clostridium difficile
3. Male, 18 CHARGE syndrome (CHD7) Atypical
1200 (0)
Choanal atresia–tracheostomy, bilateral facial nerve palsy, small
ventricular septal defect (closed spontaneously), chronic lung disease
(colonized with Pseudomonas aeruginosa)
4. Male, 26 CHARGE syndrome (CHD7) Atypical
800 (0)
Truncus arteriosus, nephrocalcinosis, chronic lung disease, enteropathy,
rotavirus
5. Male, 9 Undefined Typical
30 (0)
Truncus arteriosus, hypoparathyroidism, not dysmorphic, BCG, rotavirus
6. Male, 10 CHARGE syndrome (CHD7) Atypical
650 (0)
Fallot tetralogy, hypoparathyroidism, choanal atresia, chronic enteropathy,
norovirus
7. Male, 4 22q.11.2 deletion Atypical
1470 (0)
Patent ductus, bronchomalacia, hypoparathyroidism, CMV
8. Male, 5 22q.11.2 deletion Atypical
350 (0)
Recurrent aspiration, hypoparathyroidism, ventricular septal defect (closed
spontaneously), patent foramen ovale




Recurrent sepsis, mastoiditis, hypoparathyroidism, hypothyroidism, BCG,
rotavirus, RSV, C difficile
10. Female, 2.5 22q.11.2 deletion Typical
0
Truncus arteriosus, aortic incompetence, hypoparathyroidism,
hypothyroidism, recurrent pneumonia
11. Male, 5 22q.11.2 deletion Atypical
1250 (40)
Hypoparathyroidism, asymptomatic coronavirus
12. Male, 14 22q.11.2 deletion Atypical
370 (0)
Hypoparathyroidism, chronic lung disease, parainfluenza 3, rotavirus
RSV, Respiratory syncytial virus.
*Two transplants.
These patients subsequently died after transplantation.
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Testing for possible donor T-cell engraftment with short tandem repeats used a
previously described method.10
Clonality of T cells was assessed by using TCRVb chain spectratyping on
the CD3 population, as previously described.11 Regulatory T (Treg) cell
numbers were measured on the CD4 population by using CD25 and CD127
and intracellular staining for forkhead box P3 (FoxP3). Spectratyping was
also performed on Treg cell populations purified by means of cell sorting
based on CD41CD25HiCD1272 cells and compared with the remaining
CD4 cells. For assessment of Treg cell function, total CD41 cells were iso-
lated, and FoxP3 cells were studied for cytotoxic T lymphocyte–associated an-
tigen 4 (CTLA4) upregulation and transendocytosis of CD80 based on a
previously reported method12 modified by running the assay for a period of
21 rather than 16 hours and by fixing/permeabilizing the cells to allow staining
for total CTLA4 rather than cycling surface CTLA4.
The frequency of IFN-g–producing cells in response to either
an autologous or third-party EBV-transformed lymphoblastoid cell line
(LCL)–specific stimulation was assessed on PBMCs by using an ELISpot
assay, as previously reported.13
Histologic studies were performed on formalin-fixed tissue, including
immunohistochemical analysis, by using standard methods or as described
previously.14 Details of the antibodies used are given in theMethods section in
this article’s Online Repository.Ethics
The study was approved by the Institute of Child Health and Great Ormond
Street Hospital Research Ethics Committee covering both thymus donation,
including screening of the donors, and the transplantation procedure in the
recipient. Thymic culturewas undertaken under a license from the UKHuman
Tissue Authority.RESULTS
Patients
Details of the patients, including the genetic defect, comorbid-
ities, and infections acquired before transplantation, are shown in
Table I. Median age at transplantation was 10 months (range,
2.5-26 months). In 2 cases the molecular basis of the DGS was
undefined, although in one of these cases a putative mutation
has been found in TBX1 (analysis performed by Professor Klaus
Schwartz, University of Ulm, Ulm, Germany). Neither of these
patients was an infant of a diabetic mother. Atypical cDGS cases
outnumbered typical cases in a ratio of 2:1. Therewas no evidence
of BCG-associated disease in the 2 recipients of this vaccine. Two
patients had hypothyroidism before transplantation, the cause of
which was not established. Both had negative test results for thy-
roid peroxisomal antibodies. One had a low thyroid-stimulating
hormone value, suggesting a possible central cause, whereas in
the other the problem proved to be transient. No patients had
clear-cut autoimmune disease before transplantation.Thymic cultures
During the period of thymic culture, there was progressive
lymphoid cell depletion and a reciprocal increase in the
proportion of epithelial cell adhesionmolecule (EpCam)–positive
thymic epithelial cells (TECs; Fig 1, A-C). A small fraction of T
cells remained, with a predominance of single-positive CD4 cells
(Fig 1,D), which could be induced to activate and proliferate (Fig
1, E and F). Histologic sections of thymic slices before and after
FIG 1. Analysis of cellular composition of thymic slices by using flow cytometry at different time points
during culture. A, Dot plots show representative anti-CD45 versus EpCam1 staining. Percentages of
EpCam11CD452 cells are given in the regions shown. Histograms show anti–HLA-DR staining gated on
the EpCam11CD452 population shown in the dot plots. B, Number of live cells recovered showing the over-
all number of thymocytes and number of CD4/CD8 double-positive (DP) thymocytes retrieved per milligram
of tissue. C, Percentage of cells that were CD452EpCam11HLA-DR1 (as a frequency of the live gate). D, Pro-
portion of cells in each thymocyte subset based on CD4 and CD8 surface expression. E,When stimulated for
5 days, thymocytes from day 15 slices proliferate. CFSE, Carboxyfluorescein succinimidyl ester. F, When
stimulated for 72 hours, CD4 single-positive thymocytes from day 22 slices upregulate the activation marker
CD25.
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lymphoid cells could be seen. There was preservation of a
‘‘network’’ of epithelium seen on cytokeratin (CK) staining,
with CK5 and CK14 staining predominantly medullary thymic
epithelial cells (mTECs) and CK8 staining both mTECs and
cortical thymic epithelial cells (cTECs; CK14 data are not shown;
see Fig E1 in this article’s Online Repository at www.jacionline.
org).Clinical outcomes
The surgical procedure was well tolerated in all patients. There
were no wound infections or problems with wound healing. The
‘‘dose’’ of thymus transplanted ranged between 8 and 18 g/m2
body surface area.
Of the 8 patients with atypical cDGS, all received cyclosporine,
but 3 did not receive ATG because of concerns over potential
worsening of pre-existing viral infections. One patient (P11) with
atypical cDGS additionally received 2 courses of alemtuzumab to
control inflammatory features within 3 months before
transplantation.
Nine of the 12 patients are alive at a median follow-up time of
49 months (range, 21-80 months). Two patients (P7 and P12) died
at 8 months and 2 weeks, respectively, after transplantation frompre-existing viral infections: disseminated cytomegalovirus
(CMV) and parainfluenza 3 pneumonitis, respectively. ATG had
been withheld in both of these. One further patient died of
cerebral hemorrhage associated with immune thrombocytopenia
at 23months after transplantation. In P1 a first thymic graft did not
survive, and she received a second successful graft after
12 months. More clinical detail of this case is given in
the Results section in this article’s Online Repository at
www.jacionline.org.
Clinical outcomes in survivors have generally been good, with
exceptions mainly from autoimmune problems or other non-
immunologic aspects of DGS (Table II). All had thymopoiesis, as
evidenced by detection in the blood of naive T cells with TRECs
with or without additional evidence from biopsy specimens
showing the features of thymopoiesis.
Skin rashes. Three patients, P1 (after the second trans-
plantation), P2, and P6, had skin rashes early (3-6 weeks) after
transplantation. They underwent skin biopsy, which showed a
nonspecific dermatitis similar to the spongiotic dermatitis previ-
ously described in these cases. No donor DNA could be detected
in the skin or blood in any of these patients.
Infections cleared. Patients were able to clear a range of
infectious agents after transplantation, including those present
before and those acquired after transplantation (Table II). Both
TABLE II. Clinical outcome in patients surviving beyond 12 months
Patient





ongoing treatments Other problems




Yes Thyroxine Enteropathy resolved
Feeding problems
Hypoparathyroidism

















3. M, 67 RSV, parainfluenza 3
Metapneumovirus,
EBV (primary)









Early transient AIHA Yes Azithromycin prophylaxis Nephrocalcinosis
Chronic lung disease
Respiratory tract infections (mild)
Enteropathy resolved
5. M, 49 mo BCG, rotavirus
Parainfluenza 3
None Yes Azithromycin prophylaxis Hypoparathyroidism
Chronic lung disease
No respiratory tract infections
Complex congenital heart–stable














Chronic secretory otitis media
























Boldface type indicates an infection that was present before transplantation.
AIHA, Autoimmune hemolytic anemia; GH, growth hormone; ITP, immune thrombocytopenia; RSV, respiratory syncytial virus.
*1 3 105 copies/mL of blood.
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ized severe inflammatory response at the inoculation site and in
regional lymph nodes as T-cell reconstitution occurred. In P3 a
primary EBV infection occurred 15 months after transplantation.
He was able to clear this infection, although low-level EBV
viremia persisted for 18 months before clearing. P2, who received
chronic immunosuppression, managed to clear a number of viral
infections.
Autoimmunity. Some form of autoimmune complication
occurred in 7 of the 10 patients surviving to 12 months (Table II).
This took one of 2 forms: very early onset before evidence of
T-cell immune reconstitution or onset at or after T-cell
reconstitution. More details of the autoimmune/inflammatory
complications in each patient are provided in the Results section
in this article’s Online Repository (see Table E1 in this article’s
Online Repository at www.jacionline.org). Two cases (P4 andP9) were in the early-onset category, both with hemolytic anemia,
which responded to treatment and did not recur. In 5 other
patients, autoimmune problems occurring at or after the time of
T-cell reconstitution comprised mainly cytopenias, thyroiditis,
or both. The latter was associated with the presence of
anti-thyroid peroxisomal antibodies. A number of other transient
autoimmune/inflammatory phenomena also occurred in some
patients at or soon after immune reconstitution.
It was not possible to identify any association between the
development of autoimmunity and any methodological factors,
including the choice of thymus donor, thymic culture medium
used, amount of tissue transplanted, or use of ATG conditioning.
Six of the 10 patients surviving to 12 months had partial HLA
matching at 1 to 5 loci at 4-digit resolution typing (see Table E2 in
this article’s Online Repository at www.jacionline.org). The 3
patients without any autoimmune complications all fell into this
FIG 2. T-cell reconstitution after transplantation. Dotted lines indicate the 10th percentile of published
lymphocyte subset counts in healthy children aged 1 to 2 years and 2 to 5 years.15
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immunity, although in one of these this was just a transient early
hemolysis. All patients without any HLA matching experienced
autoimmunity (one with transient early hemolysis only).
A trend toward less autoimmunity in the presence of some HLA
matching was not statistically significant (Fisher exact test).Immunologic testing after transplantation
T-cell immunity. Donor leukocyte engraftment was not
detected in any of the patients. Circulating T-cell numbers in
surviving patients increased from around 5 months and naive
T cells increased from around 6 to 7 months after transplantation
(Fig 2).15 The correlation between naive cell numbers determinedby using different flow cytometric strategies is shown in Fig E2 in
this article’s Online Repository at www.jacionline.org. In general,
cell numbers achieved did not reach the normal age-related
range (see Table E3 in this article’s Online Repository at
www.jacionline.org). There was a continuing increase in naive
cell numbers up to 24months and then maintenance at a relatively
steady level. Low numbers of T cells in P2 were likely caused by
immunosuppression. No other patients received long-term
immunosuppression. TRECs showed a similar time course to
naive T cells (Fig 3, A). There was a relatively poor correlation
between TREC and naive CD4 and CD8 cell counts (see
Fig E3). Normal TCR diversity, as demonstrated by Vb spectra-
typing of CD3 cells, was achieved in 7 patients, including those
with atypical cDGS and an abnormal spectratype before
FIG 3. A, TREC levels determined on CD3 cells with the 10th percentile for in-house normal ranges for
children less than 2 years and 2 to 5 years of age. B, PHA responses: maximum counts per minute after
stimulation of isolated mononuclear cells stimulated with PHA. The dotted line indicates the 10th
percentile for in-house normal adult control subjects. C, Frequency of IFN-g–producing cells in the
patient’s PBMCs measured by using ELISpot (mean 6 SEM) in response to autologous and third-party
EBV-transformed LCLs in P3 after primary EBV infection. The 2-tailed Student t test for unpaired samples
was applied.
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www.jacionline.org). An abnormal spectratype persists in 3
patients (P2, P6, and P9). Further analysis showed a normal
CD4 spectratype in P6, whereas both CD4 and CD8 spectratypes
were abnormal in P9. Mitogen responsiveness to PHA (Fig 3, B)
improved in all patients but decreased again with immunosup-
pression in P2. For unknown reasons, it never normalized in P1.
This patient had good evidence for thymopoiesis on biopsy and
blood analysis. After primary EBV infection, PBMCs from pa-
tient 3 showed the ability to produce a good IFN-g response
against an autologous EBV-transformed LCL but responded
significantly less well to a third-party LCL (Fig 3, C).
Phenotyping of circulating cells with markers of Treg cells was
performed in 5 patients (P2, P4, P6, P9, and P10) and showed
these cells to be present in low absolute numbers, although
when expressed as the proportion of CD4 cells, there was no
difference to a healthy age range–matched control group (Fig 4,
A and B, and see Fig E5 in this article’s Online Repository at
www.jacionline.org). In P2, P4, P6, and P9 the proportions of
CD45RA1Treg cells were 6%, 32%, 8%, and 44% respectively,
whereas in control subjects the median level was 67% (range,
27% to 94%). The functional ability of CD41FoxP31 cells in 6
patients (P2, P4, P5, P6, P8, and P9) in terms of CTLA4
upregulation on activation and transendocytosis of CD80 wascomparable with adult control samples (Fig 4, C and D, and
see Figs E6 and E7 in this article’s Online Repository at
www.jacionline.org). In P9 spectratyping performed on sorted
Treg cells showed a diverse repertoire (see Fig E8 in this article’s
Online Repository at www.jacionline.org).
There was no correlation found between the level of immuno-
logic reconstitution achieved and factors relating to the choice of
thymus donor, thymic culture medium used, amount of tissue
transplanted, or use of ATG conditioning.
B-cell immunity. All patients received immunoglobulin
replacement before transplantation. Five patients stopped immu-
noglobulin at around 24 months after transplantation per the
protocol and have normal IgG levels. To date, 5 patients have been
immunized against tetanus toxoid and show protective responses.
Three received conjugate pneumococcal vaccine, and 2 of these
havemade good protective responses. One patient did not respond
to this vaccine and is being reimmunized. IgA levels were
undetectable/extremely low before transplantation in 11 of 12
patients and low (0.13 g/L) in the other. Levels have normalized
after transplantation in all survivors, with the exception of P2.
B-cell numbers remained normal (see Fig E9,A, in this article’s
Online Repository at www.jacionline.org) in all patients except
those (P2 and P4) receiving treatment with anti-CD20 mAb
(rituximab). The proportion of CD191 B cells that were
FIG 4. A and B, Cells with the Treg phenotype expressed as a percentage of CD4 cells and in absolute
numbers in patients (n 5 5) and an age-range matched control group (n 5 11). C and D, Transendocytosis
assay shows CD41FoxP31 cells in patients (n5 6) and control subjects (n5 5) incubated with anti-CD3 plus
untransfected Chinese Hamster ovary (CHO) cells or with anti-CD3 plus CHO transfected with CD80 with or
without anti-CTLA4. In Fig 4, C, upregulation of CTLA4 expression (shown asmean fluorescence intensity of
Treg cells normalized to mean fluorescence intensity of CTLA4 in that patient’s own naive conventional
T cells (as an internal negative control) is shown. In Fig 4, D, relative total fluorescence intensity of
CD41FoxP31 cells that have acquired green fluorescent protein (GFP) tagged onto CD80 as a result of
transendocytosis of CD80 is shown. This is derived from the mean fluorescence intensity of GFP multiplied
by the number of GFP1 cells to get total fluorescence intensity divided by the number of Treg cells acquired.
In both panels the patients and control subjects had equivalent results. **P 5 .0031.
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tients. This value remained relatively low compared with that in
published age-related control subjects16 in some patients,
whereas in others it was within normal limits, particularly after
2 years (see Fig E9, B).Thymic biopsy specimens
Biopsies of up to 4 transplanted thymic slices were undertaken
in 11 patients (including 1 after each transplantation in P1) at a
median time of 4 months (range, 2-8 months) after transplanta-
tion. Areas of histologically normal thymic tissuewere seen in the
muscle, including corticomedullary distinction and Hassall body
formation in 5 biopsy specimens. In these biopsy specimens
immunohistochemical staining showed abundant T (CD31) cells
with evidence of cortical thymopoiesis, as defined by the expres-
sion of terminal deoxynucleotidyl transferase, CD1a, and Ki67
and normal maturation to the late mTEC stage defined by the
expression of CK5 and CK14, claudin 4, autoimmune regulator
(AIRE), and involucrin. FoxP3 staining showed the presence of
frequent positive cells (Fig 5 and see Fig E10 in this article’s
Online Repository at www.jacionline.org). Biopsy specimens in
a further 2 cases (P8 and P9) showed less well-developed thymic
architecture but definite evidence of cortical thymopoiesis, as
defined by the presence of CD1a1 and Ki671 cortical thymocytes
(data not shown). Biopsy specimens with no evidence of
thymopoiesis were found in P1 (first transplantation), P2, P5,
and P7. In P2 and P5 it was likely the biopsy specimens ‘‘missed’’
thymus in the muscle because there was later appearance ofthymic emigrants in the blood indicating thymopoiesis. In P7,
who died of CMV, a biopsy specimen taken at 4 months showed
viable thymic epithelium but very little thymopoiesis (see Fig
E11, A-D, in this article’s Online Repository at www.jacionline.
org). CMV could not be demonstrated in this thymic tissue
(data not shown). P12 died very early after transplantation, and
a postmortem examination of transplanted thymus revealed
viable epithelium with extensive neovascularization (see Fig
E11, E and F).DISCUSSION
This study shows that transplantation of cultured thymic
epithelium can reconstitute T-cell immunity in patients with
cDGS, enabling them to control opportunistic infections and
have a quality of life not restricted by susceptibility to
infection. This confirms and adds to the results in the previ-
ously reported series,6,7 with the survival rate and level of im-
mune reconstitution achieved being similar between the 2
series. The proportion of children with autoimmune complica-
tions is higher in the present study, but because numbers are
relatively small, it is difficult to know whether this difference
is significant. In the present study novel data documenting
changes in the cellular composition of thymic slices during
culture are provided, as well as data on TREC levels achieved
and numbers, phenotype, and function of Treg cells. There is
also detailed histologic evidence on thymic biopsy specimens
to confirm full maturation of mTECs. Although only 1 of the
patients in this study did not have a recognized genetic cause
FIG 5. Histologic appearances of positive thymic biopsy specimens. A and B, Hematoxylin and eosin
staining showing medullary differentiation and Hassall body formation. Original magnification 5 310
and 340, respectively. C, Expression of FoxP3 within the thymic medulla (brown). Original
magnification5320. D,Double staining with terminal deoxynucleotidyl transferase (brown, nuclear signal)
showing immature thymocytes within the cortical area and CD3 (blue, membrane signal), highlighting
maturing T lymphocytes within the medulla. Original magnification 5 340. E, AIRE-expressing cells within
the medullary region, Original magnification 5 320. F, Double staining for AIRE (brown) and involucrin
(blue) that shows colocalization of AIRE-expressing cells, with fully mature, involucrin expressing mTECs.
Original magnification 5 340.
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including those with maternal diabetes, and showed that such
patients have an equivalent outcome.
The levels of T-cell reconstitution achieved in surviving
patients were not usually normal for age but were sufficient to
allow clearance of viral and other infections. Inmost cases normal
mitogen responsiveness was achieved, and a diverse repertoire
was demonstrated on TCR spectratyping. Circulating Treg cells
could be detected in proportions similar to those in control
children, although at lower absolute numbers, and their CTLA4-
mediated function was shown to be normal. Apart from one casein which an IFN-g response to EBV was shown, antigen-specific
T-cell responses were not assayed in this study. Such responses
were studied to tetanus and Candida species antigens in the pre-
vious series and showed positive responses in all but 1 of the sur-
viving patients.7 Most patients with follow-up of more than
2 years have been able to stop immunoglobulin, and in those
tested thus far, all have normal antibody responses to tetanus
and 2 of 3 have normal antibody responses to conjugated pneumo-
coccal vaccine. IgA deficiency was corrected in all but 1 patient.
Numbers of class-switched memory B cells remain relatively low
in some patients, but to assess the significance of this finding,
J ALLERGY CLIN IMMUNOL
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increase with time. The reason for the suboptimal numbers of T
cells achieved in most patients is not clear. It could be that insuf-
ficient thymic tissue was transplanted, but against this is the fact
that there was no correlation in this study or in the North Amer-
ican series8 between the amount of tissue transplanted and the
eventual T-cell or naive T-cell counts achieved. Nor was there
any association between counts and the type of medium used
for culture, the use of ATG, or the presence of chance overlap
of HLA antigens between donor and recipient.
We have shown here that the cultured thymus loses most of its
lymphoid cell populations during culture and is relatively
enriched for TECs. However, viable lymphoid cells capable of
proliferation are still present. These cells might be necessary for
the maintenance and growth of TECs.17 Theoretically, these cells
couldmediate graft-versus-host disease, but this was not seen, and
on blood analysis, engraftment of donor hematopoietic cells was
not detected in any patient. One situation in which thymopoiesis
might not develop is in the context of pre-existing CMVinfection,
as seen in P7 in this study and in the previous study.7,18 The
finding of viable thymic epithelium but no thymopoiesis on bi-
opsy is consistent with the possibility that this virus, the agents
used to treat it, or both might inhibit the development of thymo-
poiesis. Children with cDGS complicated by CMV infection
did not survive in either this or a previous study.
Biopsy of transplanted thymus has been shown to be helpful in
determining whether thymopoiesis is developing.18 In that report
biopsies were done at around 2 months after transplantation.
Thosewith positive results all showed evidence of cortical thymo-
poiesis, but in more than half, no thymic medulla or Hassall cor-
puscles were seen.18 In the present study biopsies were done later
(median, 4 months). In most of those with positive results, there
was clear corticomedullary differentiation and development of
Hassall corpuscles with immunohistochemical evidence that dif-
ferentiation of mTECs proceeds to the terminal stages. It is likely
that the difference in timing of the biopsies accounted for these
differences between this and the previous series.
In the present and previous series autoimmune complications
were relatively common, predominantly involving thyroiditis and
cytopenias. Some of these complications were of a transient
nature, which might reflect immune dysregulation during T-cell
reconstitution sometimes seen in other clinical situations, such as
after HSCTand in experimental models.19 Two very early cases of
autoimmunity were seen before any T-cell emergence and could
conceivably have had nothing to do with the transplant.
The reasons for the susceptibility to autoimmune complica-
tions are poorly understood. The possibility that inadequate
negative selection by non–MHC-matched mTEC contributes to
the development of autoimmunity was not supported by the
finding in this and the previous larger study8 of no beneficial effect
of chance partial HLA matching.
In conclusion, this study has strengthened the case for thymus
transplantation being the corrective treatment of choice for cDGS,
offering the possibility of immune reconstitution to a degree that
will produce a quality of life not limited by infection suscepti-
bility. Autoimmunity, a common complication, can often be
managed relatively easily, but a proportion of children can
experience serious consequences. Further work is required to
understand better the pathogenesis of this problem. As newborn
screening programs for SCID expand, more patients might
require this treatment. Further work is needed to streamline thelabor-intensive process requiring specialized facilities for gener-
ating and transplanting thymus. A model of human thymus
transplantation into the nude mouse might be useful in further
exploring this.20 Other patients who might benefit from this
approach include infants with SCID who do not have immune
reconstitution after HSCT or gene therapy because of thymic
insufficiency.
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Clinical implications: Thymus transplantation should be the
treatment of choice for infants with cDGS, except possibly in
those with severe pre-existing viral infections. The risk of auto-
immune complications is a significant issue for survivors, and
further work is needed to understand this better.REFERENCES
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METHODS
Patients
Patients referred who were already on artificial ventilation and those with
severe neurological defects likely to be life-limiting were excluded from the
study. In patients with congenital heart disease requiring corrective cardiac
surgery, thymus transplantation was delayed until at least 1 month after
surgery, or cardiac surgery was delayed until at least 3 months after thymus
transplantation. Patients continued their routine antibiotic prophylaxis with
co-trimoxazole and fluconazole until a CD4 count of greater than 3003 106/L
and a normal mitogen response were achieved. Replacement doses of
immunoglobulin were administered for a minimum of 2 years after thymus
transplantation. Additionally, during winter months, patients received
monthly intramuscular injections of palivizumab as prophylaxis against
respiratory syncytial virus.
Obtaining donor thymuses
Thymus glands totally or subtotally removed at the time of cardiac
surgery through a median sternotomy in infants with congenital heart
disease were collected with the written informed consent of the parents.
Thymus donors were selected on the basis of ABO blood group compati-
bility, absence of trisomy 21 or known other chromosomal anomalies,
absence of prior known infectious risk, and age less than 10 months. After
receipt of the thymus and during the period of tissue culture, the donor infant
and his or her mother were screened for possible transmissible diseases. This
included testing for HIV1 and HIV2, hepatitis B, hepatitis C, human T-
lymphotropic virus 1 and 2, toxoplasmosis, and syphilis in both the infant
and mother. In addition, tests were carried out on the infant for CMV (urine,
blood, and thymus tissue), EBV, adenovirus, and HHV6 (all on blood and
thymic tissue). Positive results to any of these tests resulted in the thymus
being discarded. Additionally, the donor infants were screened for 22q.11
deletion by using either fluorescent in situ hybridization or array compara-
tive genome hybridization. The donors’ mothers were asked to complete a
lifestyle questionnaire giving any risk factors for transmissible diseases.
DNA extracted from thymocytes released from the slices during culture
was stored and used for tissue typing of the donor.
Thymic culture
The thymus was prepared and cultured, as described previously.E1 Briefly,
the capsule of the thymus was removed, and it was sliced with a Stadie-Riggs
microtome (Thomas Scientific, Swedesboro, NJ) into approximately
1-mm-thick slices that were then mounted on nitrocellulose filters (Millipore,
Temecula, Calif). The filters were then placed on Spongostan surgical sponges
(FerrosanMedical Devices, Soeborg, Denmark) and bathed in culturemedium
in 9-cmPetri dishes. For the first 3 patients, thismedium comprised serum-free
CELLGRO (Invitrogen, Carlsbad, Calif), and for the remaining patients,
thymus organ medium containing 10% FBS (New Zealand sourced, heat
inactivated, and gamma irradiated) was used, as previously described.E1
Thymuses were cultured for between 14 and 21 days with daily change of
medium. Regular medium cultures were taken, as was genus-specific PCR
testing for Mycoplasma species. On the final day of culture, the medium
was subjected to gram staining and an endotoxin detection assay (Charles
River, Wilmington, Mass). The weight of each slice was estimated by
photographing the slices, measuring the area of the slice with the ImageJ
program (available from the National Institutes of Health, Bethesda, Md),
and assuming each slice was 1 mm thick with a density of 1 g/cm3.
Histologic assessment of the thymic slices was undertaken at the start of the
culture period, at 9 to 12 days of culture, and at the end of the culture period to
assess thymic epithelial viability and the degree of lymphoid depletion.
A decision on suitability for transplantation was taken on the second of these
evaluations.
Studies of the cellular composition of cultured thymus were performed on
separate cultures not destined for transplantation. Single-cell suspensions
generated from thymic slices were analyzed by using flow cytometry at
varying time points. Tissue was weighed before digestion and then teased
through a cell strainer into Dulbecco modified Eagle medium (Sigma, St
Louis, Mo) to remove some thymocytes. The remainder was finely disag-
gregated with a scalpel blade. Tissue fragments were then enzymatically
digested at 378C for 25 minutes in Dulbecco modified Eagle medium with
0.5 mg/mL DNase (Roche Diagnostics, Mannheim, Germany) and 1 mg/mL
collagenase (Roche Diagnostics) and then passed through a cell strainer.
Residual material was subjected to a second round of enzymatic digestion,
which also included 0.25% trypsin (Sigma) and 0.02% EDTA. Thymic slices
older than 7 days did not require a second digestion step to generate single-cell
suspensions.
Digested material was passed through a clean cell strainer, and cells were
washed in PBSwith 10%FBS, countedwith trypan blue, and prepared for flow
cytometry. Tissue digests were stained with fluorochrome-conjugated
antibodies to detect thymocytes and nonhematopoietic TECs. Thymocytes
retrieved from cultured slices were additionally subject to T cell–specific
stimulation (anti-CD31 recombinant human IL-2). By using flow cytometry,
activation and proliferationweremeasured by assessing upregulation of CD25
and carboxyfluorescein succinimidyl ester dilution, respectively (all reagents
were from eBioscience, San Diego, Calif).
Thymus transplantation
Thymus transplantation has been described previously.E1 Briefly, each slice
was placed into a small hole in the quadriceps muscle, and an insoluble stitch
was used to pull the muscle over the slice. Based on previous experience at
Duke University, the estimated weight of thymic tissue transplanted was
capped at a maximum of 18 g/m2 recipient body surface area.
Posttransplantation monitoring
Patients underwent regular clinical and immunologic assessment. In
addition, there was regular monitoring of thyroid function and monitoring
for the presence of anti-thyroid peroxisome antibodies. T-cell chimerism
studies were undertaken on DNA extracted from blood samples and on skin
when the appearance of rashes necessitated a skin biopsy after transplantation
to check for possible donor T-cell engraftment by using short tandem repeats
in a previously described method.E2 Biopsy of the transplanted thymus was
undertaken in most cases and involved opening one of the original surgical
wounds and taking up to 4 muscle biopsy specimens from the area of previous
slice insertion.
Immunologic analysis
Flow cytometric analysis involved labeling of whole blood with a
combination of directly conjugated mAbs, all of which were purchased
from Becton Dickinson Biosciences (San Jose, Calif). Naive CD4 T cells
were assessed by using 3 different flow cytometric strategies:
CD45RA1CD271, CD45RA1CD62L1, and CD45RA1CD311. Normal
ranges for lymphocyte subsets, naive populations, and proportions of class
switched memory B cells were based on published data.E3,E4 Mitogen
response was assessed by measuring tritiated thymidine incorporation after
stimulating isolated mononuclear cells with PHA at concentrations of 1 to
8 mg/mL. The normal range for PHA responses was based on analysis of
297 consecutive in-house healthy adult control subjects assayed over the
time course of the study (median, 31,800 cpm; range, 5,200-175,800
cpm). Thymic output was also assessed by measuring TREC levels with
real-time quantitative PCR. Age-related normal ranges for TREC levels
were based on in-house unpublished data.
Histology and immunohistochemistry
The following antibodies were used: mouse anti-human CD3; mouse
anti-human CD1a; mouse anti-human Ki67(K2); mouse anti-human CK14;
mouse anti-human CD31 (PECAM-1; all from Leica Biosystems, Buffalo
Grove, Ill); mouse anti-human CK, AE1/AE3 (1:50; Dako, Glostrup,
Denmark); rat anti–human CD3 (BD Biosciences, San Jose, Calif); rat
anti-human FoxP3 (1:200; eBioscience), rabbit anti-human claudin 4
(1:100; Zymed Laboratories, South San Francisco, Calif), mouse anti-
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human AIRE (1:5000; kindly provided by Professor P. Peterson, Univer-
sity of Tartu, Estonia)E5,E6; rabbit anti-CK5 (Covance, Princeton, NJ); rat
anti-CK8 (Developmental Studies Hybridoma Bank, University of Iowa),
mouse anti–terminal deoxynucleotidyl transferase (Dako), and mouse
anti-involucrin (Abcam, Cambridge, United Kingdom).
RESULTS
Patient and graft survival
In P1 failure of the first thymic graft to survive was evidenced
by a biopsy specimen showing no viable thymus and no
evidence of naive T cells in the circulation. This was likely
the result of an episode of severe septic shock associated with
Streptococcus faecalis central venous line infection occurring
5 days after transplantation and resulting in very poor tissue
perfusion. The patient survived the episode but had an abdom-
inal EBV-negative B-cell lymphoma that was shown to be of
host cell origin at 6 months after transplantation. After success-
ful treatment with chemotherapy and anti- CD20 mAb treat-
ment, a second transplantation procedure was undertaken in
this patient. This patient had evidence of another intra-
abdominal B-cell lymphoproliferative process 6 months after
the second transplantation, which resolved after further treat-
ment with rituximab and has not recurred after more than 5 years
of follow-up.
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Comparison of naive cell numbers by using
different strategies
Comparison of the results by using the 3 flow cytometric
strategies for detecting naive T cells showed excellent correlation
for CD4 cells, although for the CD8 analyses, the results with
CD27 correlated less well with the results fromCD62L and CD31
than these 2 methods did with each other (Fig E2).
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FIG E1. Histologic appearance of thymic slices before and after culture. A, Hematoxylin and eosin staining
before culture. Original magnification 5 34. B, Hematoxylin and eosin staining after 16 days of culture
shows lymphoid depletion but with some remaining lymphoid clusters. Original magnification 5 34.
C, CK5 (staining mTECs) at day 16. Original magnification 5 310. D, CK8 (staining predominantly cTECs)
at day 16. Original magnification 5 310.
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FIG E2. Correlation of naive T-cell counts between different stainingmethods:A-C, CD4 cells;D-F, CD8 cells.
All were stained with CD45RA plus an additional second antibody (CD27, CD31, or CD62L), and the results
between different second antibodies were compared. Each symbol represents a different patient tested at
around 24 months (range, 17-27 months) after transplantation.
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FIG E3. Correlation of naive cell counts measured by using different methods with TREC levels: A-C, CD4;
D-F, CD8. All were stained with CD45RA plus an additional second antibody (CD27, CD31, or CD62L). Each
symbol represents a different patient tested at around 24 months (range, 17-27 months) after
transplantation.
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FIG E4. TCRVb spectratyping performed on CD31 T cells in patient 8 with atypical cDGS before (A) and after
(B) transplantation, respectively.
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FIG E5. Flow cytometric strategy for enumerating Treg cells. FSC, Forward scatter; SSC, side scatter.
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FIG E6. Negatively selected CD41 cells (from PBMCs using a kit from STEMCELL Technologies, Vancouver,
British Columbia, Canada) cultured 2.5:1 with Chinese hamster ovary (CHO) cells and soluble OKT3 for
21 hours. Unstimulated is defined as CHO-blank (no transfection) or CHO cells transfected with CD80.
Patient and control subject show equivalent upregulation of CD25 and CTLA4 expression upon activation.
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FIG E7. CTLA4 mediated transendocytosis of green fluorescent protein (GFP)–tagged CD80 in a patient and
a control subject. A, Gating strategy for CD41FoxP31 cells. B, After incubation with Chinese hamster ovary
(CHO) cells. There was no uptake of GFP with CHO cells alone (left boxes), and cells acquire GFP from
CHO-CD80 (middle boxes); this uptake is blocked by anti-CTLA4 at 20 mg/mL (right boxes).
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FIG E8. TCRVb spectratyping performed on isolated Treg cells (CD41CD25hiCD1272) from patient P9
(A), conventional (non-Treg) CD4 cells from P9 (B), isolated Treg cells from an adult control subject
(C), and conventional CD4 cells from a control subject (D). Boxes in Fig E8, B, C, and D, have the same
designations as shown in Fig E8, A.
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FIG E9. A, B-cell (CD191) counts over time. Reference lines indicate median values for age-related control
subjects aged 1 to 2 and 2 to 6 years.E3 B, Class-switchedmemory cells over time. Note: There are no data on
P2. Reference lines indicate the 25th percentile for age-related control subjects aged 0 to 1, 2 to 3, and 4 to
5 years.E4
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FIG E10. Further immunohistochemical staining of thymic biopsy specimens. A, CD3 staining showing
T cells throughout the thymic tissue. Original magnification534. B, CD1a staining showing strong staining
in cortical areas consistent with thymopoiesis. Original magnification 5 32. C, Ki67 staining showing
proliferation of cortical thymocytes. Original magnification 5 34. D, CK staining in TECs (CK14). Original
magnification 5 310. E, CK5 staining showing mTEC. Original magnification 5 320. F, Claudin 4 (blue)
and AIRE (brown) staining in mature mTECs. Original magnification 5 320.
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FIG E11. Histologic appearance of biopsy specimens of patients who died of viral infections. All original
magnifications are320, except image Fig E11, B, which is310. A-D, Hematoxylin and eosin, CK14, CD3, and
CD1a staining, respectively, in patient 7 shows a nest of thymic epithelium present in the muscle but with
very few CD31 or CD1a1 lymphoid cells, suggesting little or no thymopoiesis. E and F, Hematoxylin and
eosin and CD31 staining, respectively, of a strand of thymic tissue in the muscles in patient 12 shows
extensive neovascularization at 2 weeks after transplantation.
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TABLE E1. Autoimmune problems
Disorder and notes Onset (after transplantation) Treatment Outcome
P1 Nephritis proteinuria/hematuria
Normal renal function
No biopsy specimen taken
4 mo None Resolved over 3-4 mo




Colonoscopy: pus and bleeding with
patchy lymphocytic infiltration
and cryptitis on histology
8 mo Salazopyrine
Prednisolone
Resolved over 4-5 mo
C difficile cleared early in the course
of the episode
Hemolytic anemia and moderate
thrombocytopenia
Direct antiglobulin test positive
9-10 mo Prednisolone, rituximab, high-dose
IVIG, erythropoietin, Bortezomib,
MMF, sirolimus, splenectomy
Remission after 72 mo after
splenectomy and introduction of
sirolimus
P3 None
P4 Hemolytic anemia 12 wk Prednisolone, rituximab,
erythropoietin




Died at 8 mo
P8 Hypothyroidism 8 mo L-thyroxine Ongoing
Thrombocytopenia
Mostly mild, with 2 episodes of
platelets <20 3 109/L
9 mo High-dose IVIG on 2 occasions Resolved
Neutropenia (positive anti-neutrophil
antibodies)
33 mo None Resolved over 2-3 mo
P9 Hemolytic anemia
Direct antiglobulin test positive
5 wk Prednisolone, erythropoietin Resolved over 2 mo
P10 Thrombocytopenia
Mild to moderate initially Improved
with IVIG
Decreased to 5 3 10/L at 21 mo
8 mo High-dose IVIG Died (cerebral hemorrhage) at 21 mo
P11 Hypothyroidism 13 mo L-thyroxine Ongoing
Thrombocytopenia
Mostly mild
Two severe episodes requiring
treatment
17 mo High-dose IVIG Resolved
Increased transaminases
Viral screen negative
Liver biopsy not suggestive of
autoimmune hepatitis
19 mo None Resolved after 3-4 mo
P12 None
Died at 2 wk
IVIG, Intravenous immunoglobulin; MMF, mycophenolate mofetil.
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TABLE E2. HLA typing of patients and donors
A B C DR DQ
P1 24:02, 25:01 18:01, 40:02 12:02, 02:02 04:04, 11:01 03:02, 03:01
Donor (1st) 02:01, 24:02 08:01, 44:02 05:01, 07:01 03:01, 08:01 03:01, 04:02
Donor (2nd) 02:01, 32:01 08:01, 14:01 07:01, 08:02 03:01, 07:01 02:01, 02:02
P2 26:01, 29:01 38:01, 44:03 12:02, 16:01 07:01, 13:01 03:01, 06:03
Donor 01:01, 24:02 08:01, 15:07 07:01, 03:03 01:01, 04:04 05:01, 03:02
P3 03:01, 11:01 07:02, 13:02 06:02, 07:02 07:01, 15:01 02:02, 06:02
Donor 01:01, 68:01 15:17, 35:03 07:01, 12:03 13:01, 15:01 06:02, 06:03
P4 02:01, 68:01 51:01, 51:01 07:01, 14:02 13:01, 15:02 06:01, 06:03
Donor 02:01, 11:01 51:01, 55:01 03:03, 14:02 07:01, 13:01 03:03, 06:03
P5 01:01, 02:02 07:02, 41:01 07:02, 17:01 04:05, 15:01 02:02, 06:02
Donor 03:01, 03:01 07:02, 35:01 04:01, 07:02 13:01, 15:01 05:01, 06:02
P6 03:01, 25:01 07:02, 44:02 05:01, 07:01 04:01, 04:05 03:01, 03:02
Donor 01:01, 02:01 08:01, 40:01 03:02, 07:02 03:01, 13:02 02:01, 06:04
P7 03:01, 33:03 44:03, 58:01 03:02, 16:01 03:01, 07:01 02:01, 02:02
Donor 03:01, 11:01 08:01, 40:02 07:02, 15:02 03:01, 15:01 02:01, 06:01
P8 03:01, 24:02 07:02, 39:03 07:01, 07:02 08:01, 15:01 04:02, 06:02
Donor 02:01, 02:01 18:01, 35:01 03:02, 07:01 01:01, 11:04 03:01, 05:01
P9 02:01, 29:01 07:05, 59:01 15:02, 15:02 11:01, 14:01 03:01, 05:03
Donor 03:01, 24:02 14:02, 44:02 05:01, 08:02 01:01, 15:02 05:01, 06:02
P10 02:01, 11:01 44:02, 55:01 03:03, 05:01 04:01, 04:07 03:01, 03:01
Donor 26:01, 26:01 51:01, 55:01 01:02, 03:03 01:01, 14:01 05:01, 05:03
P11 02:01, 11:01 44:02, 51:01 05:01, 16:01 11:01, 11:04 03:01, 03:01
Donor 01:01, 02:01 08:01, 45:01 06:02, 07:01 03:01, 04:01 03:01, 03:02
P12 02:01, 26:01 40:01, 44:02 03:04, 05:01 04:04, 11:01 03:01, 03:02
Donor 01:01, 24:02 15:17, 51:01 07:01, 15:02 13:01, 13:03 03:01, 06:03
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TABLE E3. T-cell reconstitution





CD3 500 (140-1,390)* 653 (70-1,420) 2,100 1,400
CD4 410 (120-1,130) 410 (50-1,010) 1,300 700
CD8 100 (10-380) 150 (10-880) 620 490
Naive CD4 44 (11-440) 200 (5-310) 950 420
TRECs/106 T cells 2,238 (320-8,807) 4,184 (1,582-24,596) 14,000 10,000
*Values are expressed as medians (ranges).
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